Company Overview - 10x Genomics has over 2,400 installed instruments[6] - The company's consumable pull-through is over $150,000[6] - 10x Genomics holds over 1,100 patents and applications[6] - There are over 2,500 publications referencing 10x Genomics' technology[6] - Approximately 50% of sales are outside the US[15] Product Platforms and Market Opportunity - The company operates across three product platforms: Chromium Single Cell, Visium Spatial, and In Situ[26] - 10x Genomics addresses a global life science research tools market estimated at $15 billion[32, 33] - The company sees a downstream clinical applications market opportunity for In Situ analysis of $10 billion[35, 36] New Product Initiatives - The company launched the CellPlex Kit in Q1 2021, reducing all-in cost by approximately 60%[41, 56] - The Low Throughput Kit launched in Q2 2021, reducing startup cost by over 60%[44, 56] - Visium for FFPE is coming in Q2 2021, solving the challenge of FFPE samples[61]

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2021 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39035 10x Genomics, Inc. (Exact Name of R ...

10x Genomics, Inc. (NASDAQ:TXG) Q1 2021 Earnings Conference Call May 5, 2021 4:30 PM ET Company Participants Eric Jaschke - Director of IR and Strategic Finance Serge Saxonov - CEO and Co-Founder Justin McAnear - CFO Brad Crutchfield - Chief Commercial Officer Conference Call Participants Doug Schenkel - Cowen & Company Tejas Savant - Morgan Stanley Patrick Donnelly - Citi Dan Arias - Stifel Nicolaus Matt Larew - William Blair Operator Ladies and gentlemen, thank you for standing by, and welcome to the 10x ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 __________________________ FORM 10-K __________________________ (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39035 10x Genomics, Inc. (Exact Name of Registrant as Specif ...

10x Genomics, Inc. (NASDAQ:TXG) Q4 2020 Results Conference Call February 17, 2021 4:30 PM ET Company Participants Serge Saxonov - CEO and Co-Founder Justin McAnear - CFO Brad Crutchfield - Chief Commercial Officer Conference Call Participants Doug Schenkel - Cowen Tejas Savant - Morgan Stanley Derik De Bruin - Bank of America David Westenberg - Guggenheim Securities Dan Arias - Stifel Patrick Donnelly - Citi Matt Sykes - Goldman Sachs Operator Ladies and gentlemen, thank you for standing by and welcome to t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39035 10x Genomics, Inc. (Exact Name ...

10X Genomics, Inc. (NASDAQ:TXG) Q3 2020 Earnings Conference Call November 10, 2020 5:00 PM ET Company Participants Eric Jaschke - Director, Investor Relations and Strategic Finance Serge Saxonov - Co-Founder, CEO & Director Justin McAnear - CFO Bradford Crutchfield - Chief Commercial Officer Conference Call Participants Tycho Peterson - JPMorgan Chase & Co. Michael Ryskin - Bank of America Merrill Lynch Doug Schenkel - Cowen and Company Patrick Donnelly - Citigroup Tejas Savant - Morgan Stanley David Westen ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 _____________________ FORM 10-Q _____________________ (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ___________ to ___________ Commission File Number: 001-39035 10x Genomics, Inc. (Exact Name of Re ...

10x Genomics, Inc. (NASDAQ:TXG) Q2 2020 Results Conference Call August 11, 2020 4:30 PM ET Company Participants Eric Jaschke - Director of Investor Relations and Strategic Finance Serge Saxonov - Co-Founder & Chief Executive Officer Justin McAnear - Chief Financial Officer Bradford Crutchfield - Chief Commercial Officer Conference Call Participants Tycho Peterson - JP Morgan Derik De Bruin - Bank of America Doug Schenkel - Cowen Luke Sergott - Evercore ISI Patrick Donnelly - Citigroup Daniel Arias - Stife ...

10x Genomics, Inc. (NASDAQ:TXG) Q1 2020 Results Conference Call May 11, 2020 4:30 PM ET Company Participants Carrie Mendivil - Investor Relations Serge Saxonov - Co-Founder & Chief Executive Officer Justin McAnear - Chief Financial Officer Brad Crutchfield - Chief Commercial Officer Conference Call Participants Tycho Peterson - JPMorgan Derik De Bruin - Bank of America Doug Schenkel - Cowen Patrick Donnelly - Citi David Westenberg - Guggenheim Securities Operator Ladies and gentlemen, thank you for standing ...